Hamlet Pharma AB (publ) (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (publ) (NGM:SELECT B) on March 31, 2023. The transaction is subject to Hamlet Pharma AB (publ) (NGM:HAMLET B) and Selectimmune Pharma AB (publ) (NGM:SELECT B) board approval. The transaction is expected to close on May 23, 2023. . Hamlet Pharma has engaged Advokatfirman Delphi as legal advisor. SelectImmune has engaged Falkenborn Advokatbyrå as legal advisor.

Hamlet BioPharma AB (publ) (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB (publ) on May 17, 2023. Following this transaction, Selectimmune Pharma merged with Hamlet BioPharma.